March 13, 2007 — The US Food and Drug Administration (FDA) has approved first-time generic formulations for rabeprazole sodium 20-mg delayed-release tablets and ranitidine HCl 15-mg/mL oral ...

TOKYO A United States appeals court ruled Monday to block generic competition to Tokyo-based Eisai’s stomach ulcer drug Aciphex. The U.S. Court of Appeals for the Federal Circuit ruled against Teva ...

Japan’s Eisai says that US regulators have granted a priority review for a new application of the firm’s proton pump inhibitor Aciphex. Japan’s Eisai says that US regulators have granted a priority ...

WIXOM, Mich., Nov. 01, 2021 (GLOBE NEWSWIRE) -- Woodward Pharma Services LLC ("Woodward"), a Michigan-based specialty pharmaceutical company focused on acquiring, licensing and commercializing branded ...

WOODCLIFF LAKE, N.J., Nov. 30, 2012 /PRNewswire/ -- Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for priority review Eisai's New Drug Application (NDA) for ...

Eisai announced that the FDA has approved Aciphex Sprinkle (rabeprazole sodium) Delayed-Release Capsules for the treatment of gastroesophageal reflux disease (GERD) in children 1–11 years of age for ...

Eisai announced that Aciphex Sprinkle (rabeprazole sodium) Delayed-Release Capsules are now available for the treatment of gastroesophageal reflux disease (GERD) in children 1–11 years old for up to ...

NEW YORK, May 11 (Reuters) - A U.S. court on Friday upheld drug companies seeking to sell cheap versions of the medicine. The court decision was a major victory for Japan-based Eisai, which derives ...